Status of Humoral and Cellular Immune Responses within 12 Months following CoronaVac Vaccination against COVID-19
Wei Zhao, Weixin Chen, Juan Li, Meng Chen, Qin Li, Min Lv, Shanshan Zhou, Shuang Bai, Yali Wang, Lichi Zhang, Peng Zhang, Jian Wang, Qun Zheng, Jiang Wu
Abstract
CoronaVac is an inactivated vaccine containing whole-virion SARS-CoV-2, which has been approved in 43 countries for emergency use as of 26 November 2021. However, the long-term immune persistence of the CoronaVac vaccine is still unknown. Here, we reported the status of the persistence of antibodies and cellular responses within 12 months after two doses of CoronaVac. Such data are crucial to inform ongoing and future vaccination strategies to combat COVID-19.
Topics & Concepts
VaccinationImmune systemCoronavirus disease 2019 (COVID-19)ImmunologySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Persistence (discontinuity)2019-20 coronavirus outbreakImmune statusMedicineVirologyAntibodyPandemicBiologyDiseaseOutbreakInfectious disease (medical specialty)PathologyEngineeringGeotechnical engineeringSARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesVaccine Coverage and Hesitancy